Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 43 peer-reviewed journal articles Updated
Endocrinology · Antibody-Mediated Transient Congenital Hypothyroidism

Biology and Diagnosis of Antibody-Mediated Transient Congenital Hypothyroidism

At a Glance

Antibody-mediated transient congenital hypothyroidism is a temporary condition in newborns caused by maternal thyroid-blocking antibodies crossing the placenta. The baby's thyroid is normal and will resume functioning once the mother's antibodies naturally clear from their system in a few months.

It can be overwhelming to hear that your newborn has a thyroid condition, but understanding the biology of antibody-mediated transient congenital hypothyroidism can provide significant peace of mind. In this specific form of hypothyroidism, your baby’s thyroid gland is structurally normal and healthy [1][2]. The issue is not a permanent defect in the baby, but rather a temporary “blockade” caused by the mother’s immune system during pregnancy [3][4].

Please hear this: This is an autoimmune reaction that you have no control over, and nothing you did or didn’t do during pregnancy caused this.

The “False Signal”: How Maternal Antibodies Work

During pregnancy, a mother’s body naturally shares protective IgG antibodies with the fetus to provide immune defense after birth [5][6]. However, if a mother has certain autoimmune conditions (like Hashimoto’s or sometimes Graves’ disease), her body may produce TSH-receptor blocking antibodies (often abbreviated as TRB-Ab, TSBAb, or TBII) [7][3].

These antibodies cross the placenta and enter the baby’s bloodstream [3][8]. Once there, they act like a “key” that fits into the lock of the baby’s thyroid gland (the TSH receptor) but refuses to turn it. By sitting in that lock, they prevent the baby’s own Thyroid Stimulating Hormone (TSH) from sending the signal to produce thyroid hormone [9][10]. This temporarily shuts down the baby’s thyroid production, leading to a positive newborn screen for hypothyroidism.

Differentiating Transient from Permanent CH

When a baby is diagnosed with congenital hypothyroidism (CH), doctors must determine if it is permanent or transient (temporary).

  • Permanent CH: This can happen in two ways. Thyroid dysgenesis occurs when the thyroid gland itself is missing, too small, or in the wrong place [2][11]. Dyshormonogenesis occurs when the gland is present (and sometimes enlarged), but has a genetic defect preventing it from making hormone correctly [1].
  • Transient CH (Antibody-Mediated): The baby has a perfectly formed thyroid gland in the correct location, but it is being blocked by maternal antibodies [3][4].

Because maternal antibodies eventually clear out of the baby’s system—typically over the course of two to three months—this condition is temporary [12]. Once the mother’s antibodies are gone, the baby’s thyroid can begin functioning normally on its own [3].

Confirming the Diagnosis

To confirm that the hypothyroidism is caused by antibodies rather than a permanent issue, several tests are typically performed:

  1. Newborn Screen: The initial alert that TSH levels are high or T4 levels are low [13].
  2. Thyroid Ultrasound: This is a crucial tool. If the ultrasound shows a eutopic gland (a gland of normal size in the correct location), it leaves open the possibility of a transient issue [1][14]. While a normal ultrasound is required for this diagnosis, it doesn’t entirely rule out permanent CH (like dyshormonogenesis), which is why antibody testing is needed.
  3. Maternal and Infant Blood Tests: Doctors test for specific antibodies (TRAb, TBII, or TSBAb) in both the mother and the baby [3][7]. High levels in the mother are a strong indicator of this condition [7][15].
  4. Thyroid Scintigraphy (Optional): In some cases, a specialized scan may be used to see if the thyroid is “trapping” iodine correctly. In antibody-mediated cases, the scan might show no activity (a “white scan”) even though a gland is present on ultrasound, because the antibodies are blocking the signal to work [16].

Looking Ahead

While waiting for the antibodies to clear, babies are treated with thyroid hormone replacement (levothyroxine) to support normal brain development and growth during this critical window [17].

Current medical practice often involves a “trial off” medication, typically around age 3 (or sometimes earlier if antibody clearance is confirmed), to prove the thyroid is now working independently [17][18].

In this guide

2 chapters

01

Treatment Strategy and the Weaning Phase

Learn how to treat antibody-mediated transient congenital hypothyroidism. Understand infant levothyroxine dosing, daily administration, and the weaning process.

02

Long-Term Outlook and Future Pregnancy Risks

Learn about the long-term outlook for transient congenital hypothyroidism and how to manage the risk of TRB-Ab antibodies affecting future pregnancies.

Common questions in this guide

What causes antibody-mediated transient congenital hypothyroidism?
It is caused when a mother's thyroid-blocking antibodies naturally cross the placenta during pregnancy. These antibodies temporarily block the baby's perfectly healthy thyroid gland from receiving the signal to produce thyroid hormone.
How long does transient congenital hypothyroidism last in babies?
The condition is temporary because the maternal antibodies will naturally clear out of the baby's system over time. This clearance process typically takes about two to three months after birth, allowing the baby's thyroid to start working normally.
How do doctors confirm my baby's hypothyroidism is temporary?
Doctors use a combination of tests, including a thyroid ultrasound, to confirm the gland is structurally normal and in the right place. They will also run specific blood tests on both the mother and baby to check for the presence of TSH-receptor blocking antibodies.
Will a normal thyroid ultrasound guarantee the condition is temporary?
While a normal ultrasound showing the thyroid is the correct size and in the correct location is an important first step, it does not completely rule out a permanent condition. Doctors must also perform antibody blood tests to confirm the temporary diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the specific result of my baby's newborn thyroid screen?
  2. 2.Has a thyroid ultrasound been performed to confirm my baby's thyroid gland is present?
  3. 3.Are you testing for TSH-receptor blocking antibodies (TRB-Ab or TSBAb) specifically?
  4. 4.How often will we need to repeat blood tests to monitor when the antibodies have cleared?
  5. 5.What is my baby's specific target TSH range during this early phase?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Transient vs Permanent Congenital Hypothyroidism: Does Thyroid Volume Tell the Tale?

    Ackah SA, Eugster EA, Nebesio TD, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(9)):1089-1094 doi:10.1016/j.eprac.2025.05.745.

    PMID: 40472992
  2. 2

    Congenital Hypothyroidism.

    Brady J, Cannupp A, Myers J, Jnah AJ

    Neonatal network : NN 2021; (40(6)):377-385 doi:10.1891/11-T-699.

    PMID: 34845088
  3. 3

    Transient Neonatal Hypothyroidism Followed by Hyperthyroidism Due to Maternal Thyrotropin Receptor Antibodies.

    Garrelfs M, Kamp GA, van Trotsenburg ASP

    JCEM case reports 2025; (3(3)):luaf040 doi:10.1210/jcemcr/luaf040.

    PMID: 40061242
  4. 4

    Congenital Hypothyroidism due to a Low Level of Maternal Thyrotropin Receptor-Blocking Antibodies.

    Castellnou S, Bretones P, Abeillon J, et al.

    European thyroid journal 2021; (10(2)):174-178 doi:10.1159/000509015.

    PMID: 33981622
  5. 5

    The maternal-fetal transfer of passive immunity as a mechanism of transplacental nanoparticle drug delivery for prenatal therapies.

    Tse WH, Higgins S, Patel D, et al.

    Biomaterials science 2022; (10(18)):5243-5253 doi:10.1039/d2bm00293k.

    PMID: 35912636
  6. 6

    Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates.

    Rosenberg YJ, Ordonez T, Khanwalkar US, et al.

    mBio 2023; (14(2)):e0034123 doi:10.1128/mbio.00341-23.

    PMID: 36946726
  7. 7

    Management of Neonates Born to Mothers With Graves' Disease.

    van der Kaay DC, Wasserman JD, Palmert MR

    Pediatrics 2016; (137(4)).

    PMID: 26980880
  8. 8

    Painless Thyroiditis with Thyrotropin Receptor-blocking and Receptor-stimulating Autoantibodies.

    Kamijo K

    Internal medicine (Tokyo, Japan) 2019; (58(21)):3121-3123 doi:10.2169/internalmedicine.3212-19.

    PMID: 31292406
  9. 9

    A novel method for measuring TBAb activity in TSAb- and TBAb-positive serum.

    Ochi Y, Hachiya T, Arata N

    Endocrine, metabolic & immune disorders drug targets 2015; (15(4)):315-20 doi:10.2174/1871530315666150824154909.

    PMID: 26299889
  10. 10

    Assessment of CD40L and TSAB serum level in Graves disease patients.

    Jawad AT, Fahad HM, Salih AA

    Human antibodies 2025; (33(3-4)):63-67 doi:10.3233/HAB-240036.

    PMID: 39453646
  11. 11

    The mutation screening in candidate genes related to thyroid dysgenesis by targeted next-generation sequencing panel in the Chinese congenital hypothyroidism.

    Zhang RJ, Yang GL, Cheng F, et al.

    Clinical endocrinology 2022; (96(4)):617-626 doi:10.1111/cen.14577.

    PMID: 34374102
  12. 12

    Factors modulating maternofetal transfer of IgG antibodies following SARS-CoV-2 gestational infection.

    Bentes AA, Mara Gonçalves de Oliveira Azevedo V, Lemos SMA, et al.

    Revista do Instituto de Medicina Tropical de Sao Paulo 2025; (67()):e29 doi:10.1590/S1678-9946202567029.

    PMID: 40243801
  13. 13

    Transient versus Permanent Congenital Hypothyroidism after the Age of 3 Years in Infants Detected on the First versus Second Newborn Screening Test in Oregon, USA.

    Ford GA, Denniston S, Sesser D, et al.

    Hormone research in paediatrics 2016; (86(3)):169-177 doi:10.1159/000448658.

    PMID: 27595483
  14. 14

    Permanent vs Transient Congenital Hypothyroidism: Assessment of Predictive Variables.

    Oron T, Lazar L, Ben-Yishai S, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(12)):4428-4436 doi:10.1210/jc.2018-00362.

    PMID: 30272179
  15. 15

    Study of the Factors Leading to Fetal and Neonatal Dysthyroidism in Children of Patients With Graves Disease.

    Banigé M, Estellat C, Biran V, et al.

    Journal of the Endocrine Society 2017; (1(6)):751-761 doi:10.1210/js.2017-00189.

    PMID: 29130077
  16. 16

    White Thyroid Scintigraphy.

    Zouggari S, Bsiss MA, Matrane A

    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2024; (39(3)):232-233 doi:10.4103/ijnm.ijnm_146_23.

    PMID: 39291074
  17. 17

    Newborn Screening Guidelines for Congenital Hypothyroidism in India: Recommendations of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) - Part I: Screening and Confirmation of Diagnosis.

    Desai MP, Sharma R, Riaz I, et al.

    Indian journal of pediatrics 2018; (85(6)):440-447 doi:10.1007/s12098-017-2575-y.

    PMID: 29380252
  18. 18

    Treatment Discontinuation within 3 Years of Levothyroxine Initiation among Children Diagnosed with Congenital Hypothyroidism.

    Kemper AR, Grosse SD, Baker M, et al.

    The Journal of pediatrics 2020; (223()):136-140 doi:10.1016/j.jpeds.2020.05.005.

    PMID: 32437757

This page provides educational information on the biology and diagnosis of transient congenital hypothyroidism. Always consult your pediatric endocrinologist for interpretation of your baby's specific diagnostic tests and care plan.

Get notified when new evidence is published on Congenital hypothyroidism due to transplacental passage of TSH-binding inhibitory antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.